GlassScriptPhysician profile
Ellie Mueller
NPI 1508917261
$6,215.12
in general payments reported to CMS, 2019-2025
20 companies · $2,950 in 2025
The $2,950 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $250 · 2021: $115 · 2022: $185 · 2023: $269 · 2024: $2,179 · 2025: $2,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,401 · Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,401.40 |
| Food and Beverage | $1,997.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,530.98 | 2024-2025 | Corevalve Evolut R, Aurora Ev-Icd Mri Surescan |
| Boston Scientific Corporation | $1,844.85 | 2019-2024 | Watchman Access System, Avvigo Guidance System, Watchman Flx |
| Abbott Laboratories | $520.22 | 2020-2025 | Amplatzer Talisman, Aveir, Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $236.59 | 2019-2025 | |
| Stryker Corporation | $233.82 | 2025 | Artix Mt, Flowtriever |
| Medtronic Vascular, INC. | $127.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $105.17 | 2019-2025 | Farxiga |
| Recor Medical INC | $88.17 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Pfizer INC. | $64.61 | 2024 | |
| Philips North America LLC | $63.93 | 2019 | |
| Novo Nordisk INC | $57.23 | 2025 | Wegovy, Ozempic |
| Edwards Lifesciences Corporation | $55.55 | 2023-2024 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.43 | 2024 | Jardiance |
| Penumbra, INC. | $42.40 | 2020 | |
| Chiesi USA, INC. | $40.41 | 2023-2024 | Kengreal, Cleviprex |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.48 | 2024 | Xarelto |
| Cardiva Medical, INC. | $36.52 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| E.R. Squibb & Sons, L.L.C. | $32.50 | 2024 | Camzyos |
| Abiomed | $25.19 | 2024 | Impella |
| Amgen INC. | $18.50 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellie Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.